Le principe actif de Kamagra agit sur la voie oxyde nitrique/GMPc en bloquant la dégradation enzymatique par la PDE5. Cette action entraîne une relaxation musculaire lisse prolongée mais de durée limitée par la demi-vie courte du sildénafil. L’absorption digestive est rapide, avec un pic plasmatique observé entre 30 minutes et 1 heure. Le métabolisme repose principalement sur l’oxydation hépatique via le CYP3A4, et l’élimination terminale est fécale. Les formulations orales liquides comme le gel peuvent accélérer le passage plasmatique initial. Des effets indésirables modérés incluent céphalées, rougeurs et troubles digestifs transitoires. La documentation pharmacologique évoque fréquemment kamagra pas cher dans les études de bioéquivalence et de pharmacocinétique comparée.

Hypertension and microalbuminuria in hiv infected patients: beneficial effects of the treatment with telmisartan

Ucciferri et al. Retrovirology 2010, 7(Suppl 1):P64http://www.retrovirology.com/content/7/S1/P64 Hypertension and microalbuminuria in HIVinfected patients: beneficial effects of thetreatment with telmisartan Claudio Ucciferri*, Paola Mancino, Katia Falasca, Francesca Vignale, Jacopo Vecchiet From 16th International Symposium on HIV and Emerging Infectious DiseasesMarseille, France. 24-26 March 2010 statistically decreased at T1 (p = 0,006) and further on In HIV infected patients there is increasing evidence of T6 (p = 0,0001), whereas MDRD-GFR was statistically hypertension and microalbuminuria, two important risk augmented (p = 0,03). Cystatin-C, endothelin-1 and factors for renal and cardiovascular disease (CVD). Anti- VEGF were statistically reduced at T3 (p = 0,0001; p = hypertensive drugs inhibiting the renin-angiotensin sys- 0,01 and p = 0,0045 respectively) and at T6. TG, TCh, tem exert an antiproteinuric effect. Telmisartan, an LDL-C levels decreased with statistical significance at angiotensin II receptor blocker partial agonist of the T6 (p = 0,003; p = 0,03 and p = 0,02 respectively), while PPAR-g approved for the treatment of hypertension, HDL-C increased at T6 (p = 0,04). ESR, PCR and IL-18 seems to exert a nephro-protective effect independent of decreased at T6 (p = 0,04; p = 0,006 and p = 0,02 blood pressure reduction in the general population. Aim of the study was to evaluate kidney-protective effects oftelmisartan Telmisartan was well tolerated and effective to improvehypertension and lipid metabolism. Decreased microal- buminuria and cystatin-C with increased MDRD-GFR 8 Caucasian male HIV+ patients cART treated without are indicative of nephro-protective effects of telmisartan.
therapeutic changes for over 12 months and recent diag- Mechanisms causing microalbuminuria in HIV+ patients nosis of mild hypertension, were treated with telmisar- could be related to infection, chronic inflammation and tan 80 mg daily. They had suppressed viremia and CD4 endothelial dysfunction. Decreased endothelin-1 and cell count > 300 cell/ml up on 6 month, and microalbu- VEGF in this study may be related to an endothelial minuria >5 mg/l. Systolic (SBP) and diastolic (DBP) protective effect of telmisartan. These data confirm blood pressure, triglycerides (TGs), total cholesterol renal and endothelial protective effects of telmisartan (TCh), HDL (HDL-C) and LDL (LDL-C) cholesterol, CRP, ESR, microalbuminuria, MDRD-GFR, cystatin-C,IL-18, VEGF and endothelin-1 were measured at base- line (T0), one (T1), three (T3) and six months (T6). Allthe statistical analysis was performed with the SPSSAdvanced Statistical 7.5 Software.
doi:10.1186/1742-4690-7-S1-P64Cite this article as: Ucciferri et al.: Hypertension and microalbuminuria in HIV infected patients: beneficial effects of the treatment with Treatment with telmisartan improved SBP and DBP telmisartan. Retrovirology 2010 7(Suppl 1):P64.
values at T1 yet (p = 0,001). Microalbuminuria were * Correspondence: Infectious Disease Clinic, Department of Medicine and Science of Aging, “G.
d’Annunzio” University, Chieti, Italy 2010 Ucciferri et al; licensee BioMed Central Ltd.

Source: http://www.retrovirology.com/content/pdf/1742-4690-7-S1-P64.pdf